A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

BACKGROUND: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate bi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars, Chasalow, Scott D, Berman, David
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3239318/
https://ncbi.nlm.nih.gov/pubmed/22123319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-204
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares